2006
DOI: 10.1111/j.1525-1438.2006.00411.x
|View full text |Cite
|
Sign up to set email alerts
|

Loss of p16 in recurrent malignant mixed mullerian tumors of the uterus

Abstract: Uterine malignant mixed müllerian tumors (MMMTs) are rare and highly aggressive malignancies with poor clinical prognoses. We examined for differences in the oncoprotein profiles of primary versus recurrent MMMTs. Five cases of recurrent uterine MMMT were examined by paraffin immunohistochemistry for the expression of p53, p16, P-cadherin, and Cerb-B2. P16, p53, and P-cadherin were each expressed in 100%, 80%, and 60% of the primary cases, respectively. Three cases expressed all three oncoproteins. All five ca… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

2
13
0

Year Published

2007
2007
2017
2017

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 12 publications
(15 citation statements)
references
References 37 publications
2
13
0
Order By: Relevance
“…5-year survival rates in early uterine carcinosarcomas (FIGO Stages I/II) are between 30%–46%, and 0%–10% in advanced cancers (FIGO Stages III/IV) [19]. The median survival in patients with uterine carcinosarcoma ranges between 16 and 40 months [11] with death usually occurring within 1-2 years of the initial diagnosis [71]. The prognosis of uterine carcinosarcoma is worse than that of endometrial carcinoma with adjustment for known adverse prognostic factors [25, 72].…”
Section: Prognosismentioning
confidence: 99%
See 1 more Smart Citation
“…5-year survival rates in early uterine carcinosarcomas (FIGO Stages I/II) are between 30%–46%, and 0%–10% in advanced cancers (FIGO Stages III/IV) [19]. The median survival in patients with uterine carcinosarcoma ranges between 16 and 40 months [11] with death usually occurring within 1-2 years of the initial diagnosis [71]. The prognosis of uterine carcinosarcoma is worse than that of endometrial carcinoma with adjustment for known adverse prognostic factors [25, 72].…”
Section: Prognosismentioning
confidence: 99%
“…Tumour characteristics of molecular markers such as expression of p53 in older women are associated with a shorter mean survival, while p53 negative tumours occurring in younger women have a longer survival [24, 38]. Immunohistochemical tumour expression of other cell cycle and apoptotic regulatory proteins such as p16 and Mcl-1 are also associated with longer survivals [24, 38, 71]. Trends observed in such individual series are difficult to generalize due to small sample sizes and need to be validated as predictive and/or prognostic markers with further research in larger tumour populations.…”
Section: Prognosismentioning
confidence: 99%
“…Malignant mixed Mullerian tumors (MMMT) of the uterus are rare, high-grade neoplasms comprising only 1-2% of uterine cancers [1] and 3-5% of all uterine malignancies [2]. They are the most common variety of mixed epithelial and non-epithelial endometrial tumors, with a clinically aggressive course [3,4].…”
Section: Introductionmentioning
confidence: 99%
“…[1] They occur in postmenopausal women and comprise only 1-2% of uterine cancers and 3-5% of all uterine malignancies. [2] Clinical presentation usually consists of abdominal pain, distension, and atypical bleeding. Though common in the uterus, these tumors may also arise in the ovaries, fallopian tubes and vagina.…”
Section: Introductionmentioning
confidence: 99%
“…Though common in the uterus, these tumors may also arise in the ovaries, fallopian tubes and vagina. [12345] MMMT is composed of both epithelial (carcinoma) and mesenchymal (sarcoma) elements but the component responsible for its aggressive biological behavior remains unclear. [67] Survival rates for Stages I-III are dismal ranging from 33% to 39%, respectively.…”
Section: Introductionmentioning
confidence: 99%